Affimed (NASDAQ:AFMD) Stock, Quote.Headers.trade-ideas

Affimed

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

A,3d,Illustration,Depicting,Cancer,Cells,In,The,Crosshairs,,Related

Biotech

News

Health Care

Movers

General

AFMD

Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate and significant clinical activity, highlighting potential efficacy of AFM24 with atezolizumab.

Why Is German Biotech Affimed Stock Soaring On Monday?

Intraday Update

Markets

Trading Ideas

ADRT

ADSK

BNAI

BPTH

CAMP

CGON

CNSP

COHR

CRKN

DELL

DHAC

DOGZ

DRCT

EFSH

FFIE

FOXO

GPCR

GRTX

IMCR

IPDN

ISPC

LQDA

LSCC

MBOT

MGNX

MOLN

NVAX

OLMA

Grupo Aeroportuario del Centro NorteB de CV

OMAB

PGEN

PRTG

PSNL

SAIC

SRCL

Vintage Wine Estates, Inc. - Common Stock

WBUY

YGMZ

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

medical pharma

Affimed shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 study in non-small cell lung cancer (NSCLC).

Why Affimed Shares Are Soaring

Affimed NV

WIIM

Affimed shares are trading lower. The company reported findings from a post-hoc exposure-response analysis in patients treated with 480 mg AFM24.

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) ("Affimed," or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced updated clinical data from the ongoing AFM24-102 trial of AFM24/atezolizumab combination therapy in heavily pretreated NSCLC patients. Results continue to demonstrate meaningful clinical activity in both NSCLC EGFRwt and EGFRmut patients with good tolerability. In addition, the Company reported findings from a post-hoc exposure-response analysis in patients treated with 480 mg AFM24 showing higher AFM24 exposure is associated with significantly better response rates, improved PFS and overall survival (OS). Based on these data, the future development program for AFM24 will use a dose of 720 mg weekly, a dose that has already been successfully tested in the phase 1 study of AFM24 showing a manageable safety profile.

Affimed Reports Results for Cancer Therapy in NSCLC Patients

Wells Fargo analyst Yanan Zhu maintains Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Overweight and lowers the price target from $20 to $15.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Affimed, Lowers Price Target to $15

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Buy and maintains $10 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target

<ul>
<li>AFM28, a bispecific, tetravalent innate cell engager (ICE&#xAE;) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patients</li>
<li>AFM28 demonstrates a favorable safety profile: Grade 1 and 2 Infusion related reactions (IRRs) were the main related side effect, occurring in 45% of patients; no signs of neurotoxicity or immune-related side effects were observed</li>
<li>Based on the good safety profile and likely dose-effect relationship, the evaluation of higher dose levels is planned &nbsp;</li>
</ul>
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the oral presentation of data on AFM28 at the 66th ASH Annual Meeting and Exposition. The data, derived from the first-in-human Phase 1 study of AFM28, showed promising results in R/R AML, with signs of clinical efficacy and a well-managed safety profile at doses up to 300 mg weekly.
The study included 29 heavily pretreated R/R AML patients across six AFM28 dose levels. The median number of prior treatment lines was two and 86% of patients had an adverse risk profile according to the 2022 guidelines from the European LeukemiaNet (ELN2022). AFM28 was administered intravenously once a week across six dose levels, ranging from 25 mg to 300 mg. AFM28 was well tolerated, and the most common treatment-emergent adverse events were IRRs, observed in 45% of patients. All IRRs were mild to moderate (Grade 1 or 2). One patient demonstrated grade 1 cytokine release syndrome (CRS). No neurotoxicity or signs for immune-effector related side effects were seen.
One of six patients treated at 250 mg showed a CR and stayed on treatment for 6.5 months. At the 300 mg dose level, 1 CR and 3 CRi were seen in 10 evaluable patients for a CRcR of 40%. Four of 10 patients are still on treatment with the option to deepen responses.

Affimed Reports Phase 1 Efficacy And Safety Data For AFM28 In Relapsed/Refractory Acute Myeloid Leukemia; AFM28, A Bispecific, Tetravalent Innate Cell Engager Targeting CD123 And CD16A, Achieved A 40% Composite Complete Remission Rate At The Highest Dose Level In Heavily Pretreated R/R AML Patients

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE&#xAE; with atezolizumab in non-small cell lung cancer.

Affimed to Review Clinical Data from Lung Cancer Trial on December 17

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data in a poster session at the 66th ASH Annual Meeting and Exposition. The dataset includes 22 patients from the run-in phase of the LuminICE-203 (AFM13-203) phase 2 open-label, multicenter, multi-cohort study. The trial evaluates the safety and efficacy of the combination of acimtamig (AFM13) with Artiva Biotherapeutics' allogeneic NK cell AlloNK&#xAE; in patients with R/R cHL.
Acimtamig in combination with AlloNK&#xAE; demonstrated a high overall response rate (ORR) of 86% with complete response (CR) of 55%. All patients in the study were heavily pretreated with a median of 5 (range: 2-13) prior therapies. All patients had received intensive combination chemotherapy, PD(L)1 checkpoint inhibitors and brentuximab vedotin. In addition, about two third of the patients had also received a previous stem cell transplant. The combination regimen exhibited a well-managed safety profile with no unexpected safety signals. Importantly, no cases of graft-versus-host disease (GvHD) or immune effector cell-associated neurotoxicity syndrome (ICANS) were reported.

Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%;  Complete Response Of 55% In 22 Heavily Pretreated Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Have Exhausted All Standard Of Care Treatments

&nbsp;The combination is being evaluated in the on-going LuminICE-203 multicenter, multi-cohort phase 2 trial.

The FDA Has Granted RMAT Designation To The Combination Therapy Of Affimed's Acimtamig And Artiva Biotherapeutic's AlloNK (AB101) For Relapsed Or Refractory Hodgkin Lymphoma

Cantor Fitzgerald analyst Li Watsek reiterates Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Affimed

Stifel analyst Bradley Canino maintains Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Hold and lowers the price target from $5 to $4.

Stifel Maintains Hold on Affimed, Lowers Price Target to $4

Earnings

Guidance

Affimed Cash, Cash Equivalents And Investments Of €24.1M Is Expected To Provide Cash Runway Into Q4 2025

Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.91) by 3.3 percent. The company reported quarterly sales of $155.00 thousand which missed the analyst consensus estimate of $2.00 million by 92.25 percent. This is a 92.10 percent decrease over sales of $1.96 million the same period last year.

Affimed Q3 2024 GAAP EPS €(0.94) Misses €(0.91) Estimate, Sales €155.00K Miss €2.00M Estimate

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) will release its quarterly earnings report on Thursday, 2024-11-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Affimed to report an earnings per share (EPS) of $-1.05.
The market awaits Affimed's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.11, leading to a 0.79% drop in the share price the following trading session.
Here's a look at Affimed's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.980</td>
<td>-1.540</td>
<td>-1.67</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.087</td>
<td>-1.379</td>
<td>-1.50</td>
<td>-1.7</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>20.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731506561_0.png" alt="eps graph" />
<h3>Tracking Affimed's Stock Performance</h3>
Shares of Affimed were trading at $3.76 as of November 11. Over the last 52-week period, shares are up 1.62%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/AFMD/earnings">To track all earnings releases for Affimed visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Affimed's Earnings Forecast

Offerings

Affimed N.V. Files For Mixed Shelf Offering Of Up To $20M

As Of June 30, 2024, Affimed's Cash, Cash Equivalents And Investments Were €34.4M. Based On Operating And Financial Plans Cash-runway Projected Into H2 2025.

Affimed Q2 2024 GAAP EPS €(1.01) Misses €(0.96) Estimate, Sales €154.000K Compared To €1.39M YoY

Press Releases

Affimed Reports Second Quarter 2024 Financial Results & Business Update

Affimed to Present at the Cantor Global Healthcare Conference 2024

Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma

Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

Affimed Reports Third Quarter 2024 Financial Results & Business Update

Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

Comments

Affimed

Affimed (AFMD) Forecast

Affimed (NASDAQ:AFMD) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga